#RRMM
He mirado la hora de salida y la diferencia de calado y sí, podría ser la triste realidad. No es la carroza de los RRMM, lamentablemente
November 16, 2026 at 2:01 PM
A los doce años descubres q los RRMM son tus padres y lo único q le importa es q estos años le hemos mentido...🤦‍♀️
November 18, 2026 at 7:57 AM
Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
Despite significant therapeutic advances, most patients with multiple myeloma (MM) eventually relapse and require successive lines of therapy, with progressively shorter remissions and increasing drug refractoriness [1, 2]. Treatment patterns and outcomes of relapsed/refractory MM (RRMM) patients in Asia differ substantially from those reported in Western populations due to differences in drug availability, reimbursement, healthcare infrastructure, access to clinical trials, patient and carer preferences [3], and potentially disease biology [4]. Despite these important differences, real-world data describing treatment sequencing and outcomes across Asia remain limited. We therefore conducted a multinational and multiregional Asian Myeloma Network (AMN) study to characterize real-world treatment patterns and clinical outcomes in MM patients receiving second line (2 L), third line (3 L), and fourth line (4 L) therapy, to provide a benchmark for RRMM treatment management across Asia. We performed a multicenter retrospective observational chart review study across six Asian countries and regions, including 1123 patients across 2 L (N = 626), 3 L (N = 341) and 4 L (N = 156), treated between 2020 and 2022 (Supplementary Fig. 1). The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall response rates (ORR), time to next treatment or death (TTNT), overall survival...
www.nature.com
November 11, 2026 at 3:10 PM
Louisa County School Board just approved a groundbreaking $2.678 million contract for a new elementary school, paving the way for an exciting future in education!

Click to read more!

#VA #CitizenPortal #CommunityInvestment #EducationReform #LouisaCountySchools #CivicAccountability
School Board approves $2.678 million RRMM contract for new elementary school
The Louisa County School Board voted 6-0 to approve a $2,678,054 contract with RRMM for architectural and engineering services for a new elementary school, and approved accompanying zero-cost construction change orders. The decision follows closed-session consideration of several contractual matters.
citizenportal.ai
November 4, 2026 at 8:37 AM
Page County is gearing up for a major decision on its high school future, exploring two bold options with a comprehensive study set for spring 2027!

Get the details

#PageCounty #VA #CitizenPortal #EducationReform #CommunityInvolvement #LongTermPlanning #PageCountySchools
Page County asks RRMM to study two consolidated-high-school options and sets spring 2027 timeline
The board directed RRMM to produce a comprehensive study comparing (1) a new consolidated high school on an undisclosed raw parcel and (2) converting/adding to Luray High School, with comparative cost and programming estimates and a target deliverable in spring 2027.
citizenportal.ai
November 4, 2026 at 2:44 AM
Featured Jobs today at RRMM; STUDIOS; Mammoth; Carlo Ratti Associati; Allen + Killcoyne; Tennessee Tech University & lots more! eocampaign1.com/web-...

Today's Employer of the Day is Of Possible ↓
October 30, 2026 at 6:01 PM
🆕Our Nov issue is live!

📊Trials: EXCALIBER-RRMM #multiplemyeloma, TOSYMA #breastcancer, DALY 2-EU #lymphoma, NANT #ovariancancer

📑Reviews: Reporting HRQoL in RCTs, @csoncol.bsky.social and @eortc.org recommendations

Cover: Assessment of NCCPs using AI

📖Read here: thelancet.com/issue/S1470-...
October 28, 2026 at 12:06 PM
Mieloma multiplo recidivante o refrattario RRMM: ELREXFIO* (elranatamab) di Pfizer supera i regimi terapeutici standard e raggiunge l’endpoint primario in uno studio di fase 3

Pfizer ha annunciato i risultati preliminari dello studio di Fase 3 MagnetisMM-32, che valuta ELREXFIO® (elranatamab) in…
Mieloma multiplo recidivante o refrattario RRMM: ELREXFIO* (elranatamab) di Pfizer supera i regimi terapeutici standard e raggiunge l’endpoint primario in uno studio di fase 3
Pfizer ha annunciato i risultati preliminari dello studio di Fase 3 MagnetisMM-32, che valuta ELREXFIO® (elranatamab) in monoterapia in pazienti adulti con mieloma multiplo recidivante o refrattario (RRMM) che hanno ricevuto almeno una precedente linea di trattamento con terapia anti-CD38 (daratumumab o isatuximab) e lenalidomide. All'analisi intermedia predefinita per l'efficacia, lo studio ha raggiunto il suo endpoint primario di sopravvivenza libera da progressione (PFS), valutato da una revisione centrale indipendente in cieco (BICR).
www.saluteh24.com
October 28, 2026 at 10:03 AM
What the etentamig BLA rests on: phase 3 CERVINO (n=393) in RRMM, with 12-month OS of 87.9% vs 72.0% and CRS in 39.5% of patients. The OS efficacy boundary was not crossed. www.targetedonc.com/view/bla-sub...
BLA Submitted for Etentamig in Relapsed/Refractory Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
www.targetedonc.com
October 27, 2026 at 5:17 PM
Explore a complimentary CME series focused on overcoming access challenges, applying emerging clinical data, and learning from real-world community experiences to help optimize care across the treatment journey: clinical.med-iq.com/series/advan...
October 20, 2026 at 3:53 PM
BMS’s Zenbexus: median PFS of 42 months vs 20 months for control in Phase III EXCALIBER-RRMM. One analyst noted, cross-trial, the result didn’t reach the magnitude seen in bispecific or CAR-T trials. So where does it fit?

Trial Tuesday. Read it here...
www.capsul.news/trial-tuesda...
October 13, 2026 at 10:13 AM
CARTITUDE-2 five-year data: 50% of relapsed/refractory myeloma patients remained progression-free after a single cilta-cel infusion. Overall survival figures follow.
CARVYKTI: half of earlier-line myeloma patients free at five years
Five-year CARTITUDE-2 data show 50% of RRMM patients remained alive and progression-free after a single cilta-cel infusion, with overall survival at
biotech.disruptsmedia.com
October 10, 2026 at 8:00 PM
🗞️ Just in: The phase 3 EXCALIBER-RRMM trial met its second dual primary end point, with iberdomide plus daratumumab/dexamethasone extending PFS vs DVd in patients with R/R multiple myeloma #mmsm #oncology

Read more: www.onclive.com/view/iberdom...
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma | OncLive
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
www.onclive.com
October 8, 2026 at 3:40 PM
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory #MultipleMyeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial. www.thelancet.com/journals/lan...
Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, co...
Iberdomide, daratumumab, and dexamethasone significantly improved MRD-negative complete response compared with daratumumab, bortezomib, and dexamethasone. The most common grade 3 or grade 4 adverse ev...
www.thelancet.com
October 2, 2026 at 9:22 AM
Cilta-cel delivers five-year progression-free survival in half of early-line myeloma patients in CARTITUDE-2. A single CAR-T infusion, durable remission data, and a marker for how cell therapy is reshaping first-line treatment sequencing.
CARVYKTI gives five-year remissions to 50% in early-line myeloma
Five-year CARTITUDE-2 data show half of early-line RRMM patients remained alive and progression-free after a single cilta-cel infusion, with no
biotech.disruptsmedia.com
September 28, 2026 at 8:00 AM
【iberdomide併用、再発骨髄腫のMRD陰性完全奏効が2倍】
BMSのZENBEXUS(iberdomide)を、ダラツムマブとデキサメタゾンに足したZDd療法。再発・難治性多発性骨髄腫の第3相で、MRD陰性の完全奏効率が対照の2倍になった。米国では加速承認済み。今回は第3相成績の追加である。
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
stellanews.life/technology/1...
BMS社ZENBEXUS併用療法、第3相でMRD陰性完全奏効率2倍に──再発・難治性多発性骨髄腫、米国で加速承認済み
Bristol Myers Squibb社は第3相EXCALIBER-RRMM試験の結果を発表した。iberdomide+ダラツムマブ併用療法は、対照群に比べMRD陰性完全奏効率を約2倍に高めた(41.1%対20.7%)。
stellanews.life
September 28, 2026 at 4:13 AM
Iberdomide-Dara-dex was the first approval in myeloma based on MRD-neg CR. Sagar Lonial, MD, who presented data from ph3 EXCALIBER-RRMM trial that supported the approval, said this combination is a new std of care in RRMM. #IMS26
September 26, 2026 at 8:12 AM
Priyanka Nair-Gupta, PhD, speaks about investigational D-domain BCMA CAR-T anito-cel. Early efficacy and safety of anito-cel in pivotal ph2 iMMagine-1 trial supports further exploration of anito-cel in ph2/3 trails in RRMM, NDMM. #IMS26
September 26, 2026 at 11:59 AM
Jia Xu, PhD student, shares first-in-human data for QI-019A, a novel BCMA/CD19 bispecific in vivo CAR-T therapy in RRMM after ≥2 prior therapies. Absence of ≥grade 2 CRS, ICANS, severe AEs supports potential o/p administration, she said. #IMS26
September 26, 2026 at 8:19 AM
Ph3 CERVINO findings show best-in-class safety profile for once-monthly etentamig, a novel BCMA x CD3 bispecific, and a reduced risk of death/progression by 60% vs std available treatments, in pts w/ RRMM ---Peter Voorhees, MD #IMS26
September 26, 2026 at 8:04 AM
Jeffrey Matous, MD, shares updates on the TRIlogy-1 trial of ramantamig, a BCMA & GPRC5d trispecific antibody. Response was sustained in pts who switched to Q8W dosing; 2-year PFS was >80% in pts with BCMA/GPRC5d-naïve TCE RRMM. #IMS26
September 24, 2026 at 1:43 PM
Thaaank...moooOOOOOoooo toooOOO muuuh Nooolan foOOOOOor MOO dooonating $10 MRROOOoOOOoooooooooOOOOOOOOOoooooo....mmm..rrmm...mr..
Muuh- right. Moo-!!! ShoOOoooow coOOOow art me....coOOOoow me...tf MOOMOO
September 8, 2026 at 8:22 PM
3 lines of treatment. 3 relapses. Running out of options.

China just approved a new answer: velinotamig (Weiketuo®), a BCMA/CD3 bispecific antibody that redirects T-cells to attack myeloma cells directly.

Approved Aug 27 by Fosun Pharma + Genrix Bio.

#RRMM #Biotech #China
September 2, 2026 at 7:59 AM